Midostaurin suitable groups and brief instructions for use

Midostaurin (Rydapt), as a multi-kinase inhibitor, can effectively inhibit multiple receptor tyrosine kinases including FLT3, thereby inhibiting the development and spread of cancer cells. In the face of leukemia cells carrying FLT3 mutations, midostaurin can trigger the apoptosis mechanism. In addition, in response to mastocytosis, it can block the KIT signaling pathway, control the release of histamine, and induce mast cells to undergo apoptosis. It is through these unique mechanisms of action that midostaurin performs well in the treatment of leukemia and mastocytosis, demonstrating significant therapeutic effects. The following are the specific applicable groups and brief instructions for use of midostaurin.

1. Applicable people

1. Adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive: For this group of patients, midostaurin is used in combination with standard cytarabine and daunorubicin induction therapy and cytarabine consolidation chemotherapy. It has been approved by the FDA and has shown excellent efficacy in patients with FLT3 mutation-positive AML.

2. Adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with hematological neoplasm (SM-AHN), or mast cell leukemia: Midostaurin is also used to treat these rare hematological diseases, providing patients with new treatment options.

2. Brief instructions for use

1. Medication form and dosage:

1) Patients with acute myeloid leukemia (AML): Take 50 mg twice a day, orally with food, on days 8-21 of each induction cycle and each consolidation cycle.

2) ASM, SM-AHN and MCL patients: 100 mg twice a day, orally with food. Patients should continue midostaurin until disease progression or unacceptable toxicity occurs.

2. Dose adjustment and monitoring: For ASM, SM-AHN and MCL patients, dose adjustment should be carried out strictly in accordance with the doctor's instructions. To ensure patient safety, it is recommended that patients be monitored for toxicity at least weekly during the first four weeks of treatment, every other week for the next eight weeks, and monthly thereafter during treatment.

In short, midostaurin, as an innovative targeted therapy, provides a new treatment strategy for FLT3 mutation-positive AML patients as well as ASM, SM-AHN and MCL patients. However, as with all medications, patient response needs to be monitored closely when using midostaurin to ensure the treatment is safe and effective. Patients should strictly follow the doctor's instructions during use to ensure the best therapeutic effect. There are many versions of this drug currently available, please choose yourself.